F10 and Stroke: • Apixaban is a direct FXa inhibitor indicated in Australia for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery (2.5 mg BID) and for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke (5 mg BID or 2.5 mg BID if ≥2 of the following; ≤60 kg, ≥80 years, serum creatinine level ≥133 um/L) [5].